[Chinese expert consensus on chimeric antigen receptor T-cell therapy for multiple myeloma (2026)]

Chimeric antigen receptor T-cell (CAR-T) immunotherapy has demonstrated favorable efficacy and reliable safety in relapsed/refractory multiple myeloma (MM). Since the publication of the first consensus, both the scope and depth of CAR-T clinical research and application in MM have significantly expanded. Notably, three novel B-cell maturation antigen (BCMA) -targeted CAR-T products have been approved by the National Medical Products Administration (NMPA) for clinical use. The development and application of CAR-T targeting novel targets such as GPRC5D have garnered significant attention. Breakthroughs have been achieved in salvage therapies for post-CAR-T relapse, while enhanced understanding has been gained regarding comprehensive management of the CAR-T treatment for MM. In light of these advancements, it is imperative to update the consensus guidelines on CAR-T therapy for MM to address evolving clinical requirements in this rapidly progressing field.